May 10, 2018
Lilly buys ARMO for $1.6 billion
Eli Lilly will buy ARMO BioSciences for $50 per share, or approximately $1.6 billion, the companies said Thursday.
Pharmaceuticals, Biotechnology and Life Sciences
Tag: cancer
May 8, 2018
Merck, AstraZeneca get EMA’s approval for Lynparza for women with platinum-sensitive ovarian cancer
AstraZeneca and Merck have gotten EMA’s approval of Lynparza tablets for use twice daily, as a maintenance therapy for patients…
May 3, 2018
Hikma launches Methotrexate for Inection in USA, which sold for $13 million last year
Hikma Pharmaceuticals’s US subsidiary West-Ward Pharmaceuticals has launched Methotrexate for Injection, USP in a 1g preservative-free presentation and Methotrexate Injection,…
April 20, 2018
Hikma’s USA subsidiary launches Zinecard generic, Dexrazoxane, for breast cancer
Hikma Pharmaceuticals has launched Dexrazoxane for Injection, 250mg and 500mg vials, the generic equivalent to Zinecard, through its US wholly-owned subsidiary…
April 16, 2018
Telix Pharmaceuticals’s collaboration with INSERM and ARRONAX can deliver products for greater clinical utility to cancer patients
Telix Pharmaceuticals, the specialist for radiopharmaceuticals or “molecularly-targeted radiation” (MTR), has entered into a research partnership with the French National…
April 4, 2018
Phase 3 study in second-line liver cancer patients met overall survival endpoint
Eli Lilly has announced top-line results from its Phase 3 REACH-2 study of its second-line treatment for liver cancer CYRAMZA,…
March 20, 2018
Mylan launches Mitomycin, generic cancer drug version of BMS’s Mutamycin
Mylan N.V. has launched its generic version of BMSs oncology drug Mutamycin in USA, called Mitomycin, for which it noted…
March 5, 2018
Artios, Masaryk in in-licensing deal for DNA nucleases targeting drug development
Artios Pharma has exercised its option to in-license the first nuclease drug development with Masaryk University in the Czech Republic,…
February 26, 2018
Artios Pharma welcomes experienced leader to chair its Board. Aims to make more value for investors by commercialisation of its cancer therapies
Artios Pharma has named US-based MBA, CA, CPA Pierre Legault as Chairman of its Board of Directors, to be effective immediately. Citing…
February 1, 2018
Faron to kick off developing Clevegen for cancer, as it got patent for its antibodies from European Patent Office
Faron Pharmaceuticals has gotten a patent from European Patent office, for Clever-1 antibodies, the mechanism for the Clevegen, the treatment…